In the way we’re structured, in the people we hire, in our trials and technology—and in the way we research and innovate transformative solutions on the frontiers of oncology and autoimmune disease.
Shifting toward disease-centric therapies, we seek to treat patients holistically, allowing us to target diseases and their consequences on the human body on multiple levels.
MULTIPLE MYELOMA (MM)
The current cancer treatment landscape is carved from centuries of scientific knowledge, gained by those dedicated to advancing a greater understanding of the human body. Diagnoses once thought incurable have now shifted, with new thinking, new research, new therapies, and new discoveries made possible by those who walked the path of innovation before us.1
Now, it’s our turn. We’re pioneering advancements in oncology that enhance the immune system’s ability to detect and kill cancer. Born from our patented BEAT® (Bispecific Engagement by Antibodies based on the T-cell receptor) technology platform, our Phase 1 immuno-oncology asset, ISB 1342, binds powerful immune cells called CD3 (or T cells) to CD38-expressing tumors.2 This approach has potential to treat patients with multiple myeloma, including those non-responsive or resistant to standard care.
At Ichnos Sciences, we’re working to change the therapeutic approaches of autoimmune diseases.
With a deep understanding of the body’s aberrant autoimmune response that leads to the immune system attacking healthy cells and causing inflammation, our molecule, ISB 830, is designed to block the key immune system activation factor, OX40.3 By blocking OX40 on the surface of T cells, ISB 830 down-regulates overactive T cells to “normalize” their activity and slow the immune system’s auto-reactive responses, reducing symptoms of autoimmune disease.3
ISB 830 offers an entirely new mechanism of action to treat autoimmune disease and has the potential to address a range of conditions. The treatment may change lives, and the way autoimmune diseases are treated—from now on.
Note: Assets that were previously identified as GBR XXXX are now identified as ISB XXXX.